^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    albumin-bound paclitaxel

    i
    Other names: ABI007, ABI-007, SNA-001, HC007
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    22h
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    1d
    Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (clinicaltrials.gov)
    P2, N=80, Recruiting, Stanford University | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ALK positive • ALK rearrangement • ROS1 rearrangement • EGFR positive
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel
    1d
    A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT (clinicaltrials.gov)
    P3, N=378, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New P3 trial
    |
    cisplatin • albumin-bound paclitaxel • Kaitanni (cadonilimab)
    2d
    Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 (clinicaltrials.gov)
    P1, N=28, Recruiting, University of Rochester | Active, not recruiting --> Recruiting | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Nov 2025 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • pemetrexed
    2d
    Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Oct 2028 | Trial primary completion date: Mar 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel
    2d
    Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. (PubMed, EClinicalMedicine)
    Taiho Pharmaceutical Co. Ltd.
    P2 data • Journal
    |
    CAV1 (Caveolin 1)
    |
    albumin-bound paclitaxel • Cyramza (ramucirumab)
    5d
    Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Shanghai Jiao Tong University School of Medicine
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Irene (pyrotinib) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811)
    5d
    CANOPY-1: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (clinicaltrials.gov)
    P3, N=673, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)
    5d
    SKYLINE: Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Institut Curie | Recruiting --> Active, not recruiting | N=130 --> 81
    Enrollment closed • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PD-L1 negative • ER negative
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • tiragolumab (RG6058)
    5d
    Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer. (clinicaltrials.gov)
    P2, N=39, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel
    5d
    Real-world evidence of chemotherapy effects in advanced pancreatic ductal adenocarcinoma: prognostic significance of TP53 status in gemcitabine plus nab-paclitaxel therapy. (PubMed, ESMO Gastrointest Oncol)
    Gemcitabine plus nab-paclitaxel (GnP) and FOLFIRINOX (FFX) therapies are widely used to treat advanced pancreatic ductal adenocarcinoma (PDAC)...In Japanese real-world data, GnP showed superior TTP compared with FFX for advanced PDAC. TP53 status may serve as a prognostic biomarker in patients receiving GnP therapy.
    Journal • HEOR • Real-world evidence
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • TP53 wild-type
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium
    5d
    Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. (PubMed, ESMO Real World Data Digit Oncol)
    54.9% of resectable patients received adjuvant chemotherapy after upfront surgery, with a median overall survival (mOS) of 33.3 months (range: 26.1 months-not reached) for those treated with Folfirinox. 79.5% of metastatic patients received first-line chemotherapy, primarily gemcitabine and nab-paclitaxel (62.6%), with a mOS of 8.7 months (range: 7.1-9.6 months)...Adherence to international guidelines varied, and clinical trial participation was low. Additionally, access to molecular testing was limited, remaining a significant challenge.
    Journal • Real-world evidence • BRCA Biomarker • MSi-H Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    gemcitabine • albumin-bound paclitaxel • irinotecan